Jan Bogaerts

Research interests

Publications

• 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00007-3

• Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)33137-4

• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30074-8

• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30777-5

• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1602253

• RECIST 1.1—Update and clarification: From the RECIST committee

  European Journal of Cancer · 2016 · https://doi.org/10.1016/j.ejca.2016.03.081

• Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv106

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62422-8

• Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

  JNCI Journal of the National Cancer Institute · 2009 · https://doi.org/10.1093/jnci/djn460

• The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

  Breast Cancer Research and Treatment · 2008 · https://doi.org/10.1007/s10549-008-0130-2

• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

  European Journal of Cancer · 2008 · https://doi.org/10.1016/j.ejca.2008.10.026

• The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

  Breast Cancer Research and Treatment · 2008 · https://doi.org/10.1007/s10549-008-0130-2

• Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

  Nature Clinical Practice Oncology · 2006 · https://doi.org/10.1038/ncponc0591

• Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj329

• Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

  Annals of Oncology · 2002 · https://doi.org/10.1093/annonc/mdf332

• Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2000 · https://doi.org/10.1200/jco.2000.18.19.3390

Current projects

No projects listed.